Background <p>In Germany the patients and many physicians are committed to provide high-standard healthcare. This is evidenced by the close coupling of research and clinical practice and the systematic integration of innovations into routine care; however, rising healthcare expenditures are driving an accelerated transfer of procedures from inpatient to outpatient settings, accompanied by the introduction of new reimbursement mechanisms.</p> Objective <p>In this context, the key question is which innovations in anal fistula treatment can currently be meaningfully implemented in Germany, sustained financially and evaluated clinically.</p> Material and methods <p>This article presents a&#xa0;narrative overview of the current reimbursement landscape for anal fistula treatment and examines the opportunities and barriers to implementing therapeutic and organizational innovations.</p> Results <p>While the hybrid diagnosis-related groups (DRG) system establishes new framework conditions for innovation, it can simultaneously shift financial risk to physicians when emergent interventions are underrepresented in bundled payment schemes.</p> Conclusion <p>A well-designed implementation of supplementary reimbursement schemes with transparent cost structures, rigorous quality assurance and robust data transparency can safeguard patient safety and support evidence-based decision making. Because the current hybrid-DRG system does not adequately provide such mechanisms, the pressure to innovate increasingly falls on the clinical practice, with a&#xa0;particular focus on organizational and procedural development.</p>